Eli Lilly and Company
[1,2,4]TRIAZOLO DERIVATIVES AS PDE1 INHIBITORS FOR THE TREATMENT OF DIABETES
Last updated:
Abstract:
The present invention provides a compound of Formula I: wherein X is CH.sub.2CH.sub.2, CH.sub.2CH.sub.2CH.sub.2, OCH.sub.2, or CH.sub.2O; and R is ethyl, n-propyl, cyclopropyl, or cyclobutyl; or a pharmaceutically acceptable salt thereof; with the proviso that when X is CH.sub.2CH.sub.2, then R is other than cyclopropyl; for use as a human PDE inhibitor. ##STR00001##
Status:
Application
Type:
Utility
Filling date:
3 Aug 2018
Issue date:
20 May 2021